葡萄糖调节蛋白78对非小细胞肺癌患者吉西他滨化疗敏感性的影响

doi:10.13481/j.1671-587x.20190321

Abstract

Abstract: Objective:To investigate the relationship between the expression of glucose-regulated protein 78 (GRP78) and gemcitabine chemotherapy in the patients with non-small cell lung cancer (NSCLC) and the effects of GRP78 on the viability of lung adenocarcinoma SPCA1 cells and the chemosensitivity of gemcitabine, and to elucidate its mechanisms. Methods:The positive expression rates of GRP78 in 32 cases of cancer tissue of the NSCLC patients were detected by immunohistochemical staining. The SPCA1 cells with high expression of GRP78 were selected as the subjects. RNA interference technique was used to down-regulate the expression of GRP78 in SPCA1 cells(interference group) and the cells treated with shNC were used as control group. MTT assay was used to detect the viabilities of SPCA1 cells in various groups.Negative control group,interference group,control+gemcitabine group,and interference+gemcitabine group were set up; colone formation assay was used to detect the colone formation rates of SPCA1 cells in various groups; Western blotting method was used to detect the expression amount of Akt, p-Akt, PI3K, and p-PI3K in the SPCA1 cells in various groups. Results:The immunohistochemical staining results showed that the positive expression rate of GRP78 in cancer tissue in the remission NSCLC patients was significantly higher than that in the no-remission NSCLC patients after treated with gemcitabine (P<0.05). The MTT assay results showed that compared with negative control group, the viability of SPCA1 cells in interference group was decreased significantly (P<0.05),and the viability of SPCA1 cells in interference+gemcitabine group was significantly decresed(P<0.05). The Western blotting results showed that compared with negative control group, the expression amounts of p-Akt and p-PI3K in the SPCA1 cells in interference group were decreased, and the expression amounts of p-Akt and p-PI3K in the SPCA1 cells in interference+gemcitabine group were decreased significantly. Conclusion:Interference of GRP78 may increase the sensitivity of gemcitabine to chemotherapy,and GRP78 may reduce the sensitivity of NSCLC patients to gemcitabine through PI3K/Akt pathway.

Key words: cancer,non-small cell lung, glucose-regulated protein 78, gemcitabine, chemosensitivity

CLC Number:

R734.2

WANG Zhijing, SU Rongjian, DU Xiaoyuan. Effects of GRP78 on sensibility of gemcitabine on patients with NSCLC[J].Journal of Jilin University(Medicine Edition), 2019, 45(03): 595-600.

References

[1] ULIVI P, ZOLI W, CAPELLI L, et al. Target therapy in NSCLC patients:Relevant clinical agents and tumour molecular characterisation[J].Mol Clin Oncol, 2013, 1(4):575-581.
[2] FAES S, DORMOND O. PI3K and AKT:unfaithful partners in cancer[J]. Int J Mol Sci, 2015, 16(9):21138-21152.
[3] TUYA N, WANG Y, TONG L, et al. Trichosanthin enhances the antitumor effect of gemcitabine in non-small cell lung cancer via inhibition of the PI3K/AKT pathway[J]. Exp Ther Med, 2017, 14(6):5767-5772.
[4] FU R, YANG P, WU H L, et al. GRP78 secreted by colon cancer cells facilitates cell proliferation via PI3K/Akt signaling[J]. Asian Pac J Cancer Prev, 2014, 15(17):7245-7249.
[5] GIFFORD J, HILL R. GRP78 influences chemoresistance and prognosis in cancer[J]. Current Drug Targets, 2018, 19(6):701-708.
[6] 王立文, 沈晓洁, 林彬. 非小细胞肺癌中lncRNA MVIH与吉西他滨耐药的相关性研究[J]. 重庆医学, 2017, 46(7):946-948.
[7] CHEN Y, HUANG Y, CHEN D M, et al. RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine[J]. OncoTargets Ther, 2018, 11:5579-5589.
[8] XU C, YU Y, DING F. Microarray analysis of circular RNA expression profiles associated with gemcitabine resistance in pancreatic cancer cells[J]. Oncol Rep, 2018, 40(1):395-404.
[9] XIONG G, HUANG H, FENG M, et al. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1):76-87.
[10] WANG Y, SUI Y, YAN K, et al. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance[J]. Oncol Rep, 2015, 33(4):1699-1706.
[11] LEE J, YOON Y, LEE S. GRP78 regulates apoptosis, cell survival and proliferation in 5-Fluorouracil-resistant SNUC5 colon cancer cells[J]. Anticancer Res, 2017, 37(9):4943-4951.
[12] LIZARDO M, MORROW J, MILLER T, et al. Upregulation of glucose-regulated protein 78 in metastatic cancer cells is necessary for lung metastasis progression[J]. Neoplasia, 2016, 18(11):699-710.
[13] WANG Y, WANG J H, ZHANG X L, et al. Endoplasmic reticulum chaperone glucose-regulated protein 78 in gastric cancer:An emerging biomarker[J]. Oncol Lett, 2018, 15(5):6087-6093.
[14] DANESHMAND S, QUEK M L, LIN E, et al. Glucose regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival[J]. Hum Pathol, 2007, 38(10):1547-1552.
[15] RUI L, GU Y, HE W, et al. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells[J]. Oncotarget, 2017, 8(12):19354-19364.
[16] CHIOU J F, TAI C J, HUANG M T, et al. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma[J]. Ann Surg Oncol, 2010, 17(2):603-612.
[17] JENIFER B, HUANG W, ZELENIAK A E. Expression of GRP78 master regulator of the unfolded protein response increases chemoresistance in pancreatic ductal adenocarcinoma[J]. Am Associat Cancer Res, 2016, 15(5):1043-1052.
[18] ZHANG Z, ZHANG M, LIU H, et al. AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells[J]. J Cell Biochem, 2018, 120(1):756-767.
[19] CHEN Y, HUANG W, SUN W, et al. LncRNA MALAT1 promotes cancer metastasis in osteosarcoma via activation of the PI3K-Akt signaling pathway[J]. Cell Physiol Biochem, 2018, 51(3):1313-1326.
[20] 胡丽娜, 彭兴春, 郭显智, 等. 抑制Notch和PI3K/Akt信号通路对食管腺癌细胞增殖、侵袭及迁移的影响[J]. 肿瘤防治研究, 2016, 43(8):653-658.
[21] ZHENG Z, ZHOU X, CAI Y, et al. TEKT4 promotes papillary thyroid cancer cell proliferation, colony formation, and metastasis through activating PI3K/Akt pathway[J]. Endocr Pathol, 2018, 29(4):310-316.
[22] 苏宝安,许之晨,李艾恩.3.0T MR弥散加权成像评价中晚期食管鳞癌放化疗的早期疗效[J].中国医学物理学杂志,2018,35(12):1452-1456.

Effects of GRP78 on sensibility of gemcitabine on patients with NSCLC

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 7

Metrics

Comments

Recommended 0

[1]	ZAO Hang, WANG XU, LI WEI. Influence of single nucleotide polymorphisms of CDA in prognosis of advanced non-small cell lung cancer patients treated with gemcitabine [J]. Journal of Jilin University Medicine Edition, 2016, 42(02): 316-320.
[2]	YU Chun-yan,LIU Xi,YU Chun-rong,ZHANG Yu,SU Jing, LIU Yu-he,KANG Jin-song. Effect of endoplasmic reticulum stress protein in oxidative stress-induced autophagy in human cervical carcinoma Hela cells [J]. Journal of Jilin University Medicine Edition, 2014, 40(01): 1-4.
[3]	LI En-xi，YIN Wei-min，WANG Xu，MA Ke-wei. Efficacy and influencing factor analysis of GP regimen in postoperative adjuvant chemotherapy for non-small-cell lung cancer  [J]. Journal of Jilin University Medicine Edition, 2013, 39(1): 122-127.
[4]	WANG Jing,ZHAO Jian-jun,LI Yun-xia,TAN Ping,XU Shan-shan. Clinical application of ATP - tumor chemosensitivity assay of in vitro susceptibility test in treatment of pleural fluid in \|patients \|with non-small cell lung cancer [J]. J4, 2012, 38(1): 135-139.
[5]	SUN Jin-bo,XU Pei-ran,SHI Dong-lei,CAO Bin. Evaluation on clinical efficacy of Aidi injection combined with \|GP chemotherapy in treatment of  advanced non-small cell lung cancer in \|elder patients [J]. J4, 2012, 38(1): 151-154.
[6]	ZHOU Xin,WU Cheng-yi. Association of CD44 polymorphisms with chemosensitivity to anthracycline-based chemotherapy in breast cancer [J]. J4, 2012, 38(1): 110-114.
[7]	FUJing,CHEN Yu,LEI Hai-lu,LEI Tuan-jie,ZHANG Peng . Inhibitory effect of gemcitabine combined with dendritic cells on proliferation of HepG2 cells [J]. J4, 2011, 37(3): 460-464.